HC Wainwright Forecasts Strong Price Appreciation for Kyverna Therapeutics (NASDAQ:KYTX) Stock

Kyverna Therapeutics (NASDAQ:KYTX) had its price target increased by equities researchers at HC Wainwright from $20.00 to $25.00 in a research report issued on Friday, Marketbeat.com reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price objective would indicate a potential upside of 132.77% from the stock’s current price.

Several other equities research analysts have also recently issued reports on KYTX. Wall Street Zen cut shares of Kyverna Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. Weiss Ratings reissued a “sell (d-)” rating on shares of Kyverna Therapeutics in a report on Friday, March 27th. Finally, JPMorgan Chase & Co. cut their price target on Kyverna Therapeutics from $30.00 to $29.00 and set an “overweight” rating on the stock in a research note on Wednesday. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $30.00.

Kyverna Therapeutics Stock Down 0.4%

Shares of NASDAQ:KYTX opened at $10.74 on Friday. The firm’s 50 day moving average price is $9.03 and its 200 day moving average price is $8.38. The stock has a market cap of $652.88 million, a price-to-earnings ratio of -3.27 and a beta of 2.05. Kyverna Therapeutics has a fifty-two week low of $2.06 and a fifty-two week high of $13.67. The company has a quick ratio of 7.75, a current ratio of 8.15 and a debt-to-equity ratio of 0.13.

Kyverna Therapeutics (NASDAQ:KYTX) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.66) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.09. As a group, equities research analysts predict that Kyverna Therapeutics will post -3.18 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Kyverna Therapeutics

Large investors have recently bought and sold shares of the stock. Phoenix Wealth Advisors grew its holdings in shares of Kyverna Therapeutics by 17.1% during the fourth quarter. Phoenix Wealth Advisors now owns 12,300 shares of the company’s stock worth $116,000 after purchasing an additional 1,800 shares during the last quarter. Public Employees Retirement System of Ohio purchased a new stake in shares of Kyverna Therapeutics in the 3rd quarter valued at about $28,000. Federated Hermes Inc. boosted its position in shares of Kyverna Therapeutics by 36.6% in the 4th quarter. Federated Hermes Inc. now owns 20,705 shares of the company’s stock valued at $195,000 after purchasing an additional 5,547 shares during the period. Rhumbline Advisers grew its stake in Kyverna Therapeutics by 22.0% during the 1st quarter. Rhumbline Advisers now owns 31,614 shares of the company’s stock worth $61,000 after buying an additional 5,694 shares during the last quarter. Finally, Bank of America Corp DE grew its stake in Kyverna Therapeutics by 41.6% during the 4th quarter. Bank of America Corp DE now owns 21,788 shares of the company’s stock worth $81,000 after buying an additional 6,400 shares during the last quarter. Institutional investors and hedge funds own 18.08% of the company’s stock.

About Kyverna Therapeutics

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.